Management of inflammatory bowel disease
- PMID: 9447214
Management of inflammatory bowel disease
Abstract
Patients with an inflammatory bowel disease, such as ulcerative colitis or Crohn's disease, have recurrent symptoms with considerable morbidity. Patient involvement and education are necessary components of effective management. Mild disease requires only symptomatic relief and dietary manipulation. Mild to moderate disease can be managed with 5-aminosalicylic acid compounds, including olsalazine and mesalamine. Mesalamine enemas and suppositories are useful in treating proctosigmoiditis. Antibiotics such as metronidazole may be required in patients with Crohn's disease. Corticosteroids are beneficial in patients with more severe symptoms, but side effects limit their use, particularly for chronic therapy. Immunosuppressant therapy may be considered in patients with refractory disease that is not amenable to surgery. Inflammatory bowel disease in pregnant women can be managed with 5-aminosalicylic acid compounds and corticosteroids. Since longstanding inflammatory bowel disease (especially ulcerative colitis) is associated with an increased risk of colon cancer, periodic colonoscopy is warranted.
Similar articles
-
Pharmacologic therapy for inflammatory bowel disease.Am Fam Physician. 1995 Jun;51(8):1971-5. Am Fam Physician. 1995. PMID: 7762487 Review.
-
Inflammatory bowel disease.Aust Fam Physician. 2005 Apr;34(4):233-7. Aust Fam Physician. 2005. PMID: 15861742 Review.
-
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013. Dig Liver Dis. 2005. PMID: 15893279 Review.
-
Inflammatory bowel disease.N Engl J Med. 2002 Aug 8;347(6):417-29. doi: 10.1056/NEJMra020831. N Engl J Med. 2002. PMID: 12167685 Review. No abstract available.
-
[Inflammatory bowel diseases: conservative therapy].Ther Umsch. 1991 Jul;48(7):464-70. Ther Umsch. 1991. PMID: 1926006 Review. German.
Cited by
-
Establishment of a Population-based Registry of Inflammatory Bowel Diseases in Fars Province, Iran.Middle East J Dig Dis. 2012 Apr;4(2):97-101. Middle East J Dig Dis. 2012. PMID: 24829641 Free PMC article.
-
Measuring differences between patients' and physicians' health perceptions: the patient-physician discordance scale.J Behav Med. 2003 Jun;26(3):245-64. doi: 10.1023/a:1023412604715. J Behav Med. 2003. PMID: 12845937
-
Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.Drugs. 2000 Apr;59(4):929-56. doi: 10.2165/00003495-200059040-00016. Drugs. 2000. PMID: 10804042 Review.
-
Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review.Saudi Pharm J. 2016 Jul;24(4):458-72. doi: 10.1016/j.jsps.2014.10.001. Epub 2014 Oct 22. Saudi Pharm J. 2016. PMID: 27330377 Free PMC article. Review.
-
Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering.Mediators Inflamm. 2022 Jan 17;2022:9621668. doi: 10.1155/2022/9621668. eCollection 2022. Mediators Inflamm. 2022. PMID: 35082553 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources